Landscape screening identifies the lactate-modifying enzyme AARS2 as a master regulator and therapeutic target in hepatocellular carcinoma
Abstract
Background Hepatocellular carcinoma (HCC), one of the most prevalent cancers worldwide, has a high mortality owing to diagnostic challenges and therapeutic resistance. Lactate metabolism and protein lactylation play key roles in HCC progression; nevertheless, their regulatory mechanisms remain poorly understood. Objective This study aims to elucidate how lactate metabolism and protein lactylation contribute to HCC malignant progression by integrating multi-omics data, identifying key regulatory factors and exploring therapeutic strategies targeting this pathway. Design Integrated multi-omics analysis identified AARS2–AP-2γ as a key axis in HCC. Through mechanistic studies and virtual screening, we developed kukoamine A—a targeted inhibitor delivered via nanocarriers—demonstrating significant therapeutic potential. Results AARS2 was identified as a key regulator linking lactate metabolism to HCC progression through lactylation modification. It catalyses AP-2γ lactylation at K444, enhancing TRIM28 binding to promote K63-linked ubiquitination and nuclear translocation, thereby facilitating tumour progression. The inhibitor kukoamine A disrupts AARS2–AP-2γ interaction and, when delivered via zeolitic imidazolate framework-8 nanocarriers, demonstrates improved liver targeting, potent antitumour activity and synergy with PD-1 blockade, offering new strategic avenues for HCC precision therapy. Conclusion AARS2 links lactate metabolism to HCC progression via lactylation. Kukoamine A nanotherapy targeting this axis shows synergistic efficacy with immunotherapy, advancing the prospects of precision oncology.Keywords
Funding Information
- The Key R&D Program of Jiangxi Province (20223BBG71008)
- the Ganzhou Talent Project (GZSQZG202301010)
- Jiangsu Provincial Medical Innovation Centre (CXZX202203)
- the 111 Center (D17011)
- the Zhanggong Science and Technology Plan Project (2023SF05)
- the Ganzhou Science and Technology Project Young Talent Program (2022CXRC9712)
- Jiangsu Province Hospital High-level Talent Cultivation Program (CZ0121002010037)
- National Natural Science Foundation of China (82300684)
- National Natural Science Foundation of China (82460122)
- National Natural Science Foundation of China (82472862)
- National Natural Science Foundation of China (82472938)
- Jiangsu Provincial Medical Key Laboratory (ZDXYS202201)
- Jiangsu Provincial Frontier Technology Research and Development Program (BF2024053)
- Guangxi Key Reaserch and Development Program (GuikeAB25069034)
- Natural Science Foundation of Jiangxi (20232ACB206006)
- Natural Science Foundation of Jiangxi (20242BAB23074)
This publication has 44 references indexed in Scilit:
- Metabolite to Modifier: Lactate and Lactylation in the Evolution of TumorsMedcomm, 2025
- High-glucose-associated YTHDC1 lactylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapyCell Reports, 2025
- Metabolic reprogramming in cancer and senescenceMedcomm, 2025
- Nano Sim@ZIF8@PDA modified injectable temperature sensitive nanocomposite hydrogel for photothermal/drug therapy for peri-implantitisCarbohydrate Polymers, 2025
- Hierarchical Targeting Nanodrug with Holistic DNA Protection for Effective Treatment of Acute Kidney InjuryAdvanced Science, 2024
- Chitosan and gelatin based sprayable hydrogels incorporating photothermal and long-acting antibiotic sterilization for infected wound management with shape adaptabilityCarbohydrate Polymers, 2024
- Innate immune regulatory networks in hepatic lipid metabolismJournal of Molecular Medicine, 2019
- Aminoacyl-tRNA synthetases, therapeutic targets for infectious diseasesBiochemical Pharmacology, 2018
- The Science and Translation of Lactate Shuttle TheoryCell Metabolism, 2018
- Surface plasmon resonance applications in clinical analysisAnalytical and Bioanalytical Chemistry, 2014